SAIL Fusion

Executive Summary

SAIL Fusion is a medical device company pioneering the application of AO fusion principles to the sacroiliac (SI) joint, addressing a significant unmet need in the treatment of SI joint dysfunction. The company's approach builds on decades of validated orthopedic fusion techniques—minimal tissue disruption, thorough joint preparation, and rigid fixation—which have been successfully applied to other joints such as the ankle. By adapting these principles to the SI joint, SAIL Fusion aims to improve surgical outcomes, reduce complications, and enhance patient recovery. Founded in 2015 and headquartered in Carlsbad, California, the company operates in the medical devices sector with a focus on spine and orthopedic surgery. While still in a relatively early stage, SAIL Fusion's technology has the potential to set a new standard of care for SI joint fusion, a procedure that has historically lacked consistent methodology and evidence. The company's success hinges on clinical validation, regulatory clearance, and market adoption among spine surgeons.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) Clearance for SI Joint Fusion System65% success
• Q4 2026Publication of First Clinical Study Results70% success
• H2 2026Strategic Partnership or Distribution Agreement50% success